Nanobody-engineered CLL-1 CAR T cells: A strategy for safer targeting in acute myeloid leukemia

In our recent publication in Cancer Research Communications, “Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity,” we developed a next-generation nanobody-based chimeric antigen receptor (CAR) T platform targeting CLL-1 for acute myeloid leukemia (AML). Leveraging llama-derived single-domain antibodies (VHHs), we engineered highly specific CAR constructs against CLL-1 and CD33 and systematically evaluated their functional performance across in vitro and in vivo models.